论文部分内容阅读
[目的]探究西妥昔单抗联合氟尿嘧啶、伊立替康治疗HER2阳性胃癌的临床疗效。[方法]选取我院2011年1月~2013年1月HER2阳性晚期胃癌42例,分为西妥昔单抗组和化疗组,化疗组患者使用氟尿嘧啶、伊立替康治疗,西妥昔单抗组在化疗组的基础上联合西妥昔单抗。治疗4个疗程后,评价2组的治疗有效率、疾病控制率、不良反应。随访2年,统计2组的生存率和生存期。[结果]西妥昔单抗组治疗有效率和疾病控制率均较化疗组高,分别为52.2%36.8%,78.3%57.9%,差异有统计学意义(P<0.05)。西妥昔单抗组与化疗组比较安全性相对较好,但是生存期差异无统计学意义。生存率西妥昔单抗组较高(78.3%)。[结论]化疗药物的基础上联合靶向药物治疗晚期胃癌具有一定的临床推广价值。
[Objective] To investigate the clinical efficacy of cetuximab plus fluorouracil and irinotecan in the treatment of HER2-positive gastric cancer. [Methods] Forty-two patients with HER2-positive advanced gastric cancer from January 2011 to January 2013 in our hospital were divided into cetuximab group and chemotherapy group. Patients in chemotherapy group were treated with fluorouracil and irinotecan, and cetuximab Group on the basis of chemotherapy combined with cetuximab. After 4 courses of treatment, the treatment efficiency, disease control rate and adverse reactions in 2 groups were evaluated. Followed up for 2 years, the survival rate and survival rate were calculated in 2 groups. [Results] The efficacy and disease control rate of cetuximab group were higher than that of chemotherapy group (52.2% 36.8%, 78.3% 57.9%, respectively), the difference was statistically significant (P <0.05). Cetuximab group and chemotherapy group safety is relatively good, but the difference in survival was not statistically significant. The survival rate was higher in the cetuximab group (78.3%). [Conclusion] Chemotherapy based on the combination of targeted drugs for the treatment of advanced gastric cancer has some clinical value.